A non-profit organization called Institute for Clinical and Economic Review (ICER) found that the U.S. spends around US$ 28,000 Mn every year for the treatment of multiple sclerosis. This will fuel demand for multiple sclerosis drugs, which will drive the global “Multiple Sclerosis Drugs Market”. The above information was shared by Fortune Business Insights in a report, titled “Multiple Sclerosis Drugs Market Size, Share and Global Trend By Drug Class (Immunomodulatory, Immunosuppressant, Interferons, Others), By Route of Administration (Oral, Injection), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Geography Forecast till 2025.” Multiple sclerosis directly impacts the brain and spinal cord of a body. Consequently, multiple sclerosis symptoms include visual disturbances, memory and thinking problems, difficulties in coordination, and muscle weakness.
Leading Players operating in the Multiple Sclerosis Drugs Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Pfizer, Inc.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386
Mayzent’s FDA Approval Propels Growth of the Market
Several pharmaceuticals companies are undergoing clinical trials for the treatment of multiple sclerosis. Companies are putting efforts to develop innovative therapies in multiple sclerosis radiology for patients suffering from this disease. Considering this, Adamas Pharmaceuticals is undergoing phase 3 of a clinical trial on an investigational amantadine agent called ADS-5102. This oral therapy is conducted to determine if multiple sclerosis or MS patients can improve their walking speed. The U.S. FDA granted approval of a drug called Mayzent to Novartis. This is the first-ever treatment for patients suffering from secondary progressive multiple sclerosis or SPMS. Drugs like these will improve the patient’s quality of life, which will contribute to the growth of the market.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386
Detailed Table of Content:
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Market Trends
- Key Insights
- Prevalence of Multiple Sclerosis – For Key Countreis, 2018
- Regulatory Scenario – For Key Countries
- Patent Snapshot
- New Drug Class Launch
- Pipeline Analysis
- Key Industry Developments – Mergers, Acquisitions and Partnerships
- Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- Market Analysis, Insights and Forecast – By Route of Administration
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- Market Analysis, Insights and Forecast – By Region
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/multiple-sclerosis-drugs-market-100386
Reasons to Purchase this Report:
- Comprehensive analysis of the Multiple Sclerosis Drugs Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
North America Generates the Maximum Revenue Owing to Rising FDA Approvals
North America is expected to dominate the global multiple sclerosis drugs market through the forecast years. Novel drugs manufactured are increasingly getting FDA approvals and these companies are planning to focus on commercialization of drugs. Influenced by this, the multiple sclerosis drugs market share is likely to expand in this region. Moreover, the region is worth US$ 13,826.7 Mn and owing to the mounting cost of drugs, the demand for multiple sclerosis treatment increases. Furthermore, the presence of potential drug candidates in North America is expected to create growth opportunities for the market during the forecast period.
Apart from North America, Europe is also anticipated to grow in the market owing to maximum support from government. Europe is the second-most leading region in the global market owing to rising per capita spending on healthcare.
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245